Table 2.

Associations between DNA methylation levels and risk of precancerous gastric lesions

SGCAGIMInd DYS/DYS
Methylation quartile levelsNNORa (95% CI)PtrendNORa (95% CI)PtrendNORa (95% CI)Ptrend
PCDH7
 Q1 = 0%74501.00551.00761.00
 Q2 0–<5.71%31311.21 (0.64–2.29)271.15 (0.60–2.19)290.89 (0.43–1.82)
 Q3 5.71%–<15.65%41441.42 (0.78–2.57)461.33 (0.74–2.38)561.52 (0.83–2.78)
 Q4 ≥15.65%35501.82 (0.97–3.43)0.06411.27 (0.68–2.38)0.4611.46 (0.79–2.70)0.1
PCDH10
 Q1 <17.57%63521.00271.00351.00
 Q2 17.57%–<43.89%36421.40 (0.77–2.55)442.41 (1.25–4.65)562.59 (1.32–5.09)
 Q3 43.89%–<73.48%34381.30 (0.70–2.42)503.15 (1.63–6.09)563.02 (1.50–6.09)
 Q4 ≥73.48%26371.63 (0.85–3.14)0.8453.95 (1.98–7.87)<0.001704.75 (2.33–9.70)<0.001
PCDH17
 Q1 = 0%73691.00421.00481.00
 Q2 0%–<7.40%17130.70 (0.31–1.59)60.50 (0.18–1.74)141.00 (0.42–2.38)
 Q3 7.40%–<41.53%30371.37 (0.73–2.58)371.99 (1.02–3.87)371.83 (0.92–3.64)
 Q4 ≥41.53%16190.95 (0.43–2.09)0.7535.09 (2.48–10.42)<0.001533.65 (1.76–7.56)<0.001
PCDH20
 Q1 <1.53%39371.00401.00551.00
 Q2 1.53%–<7.12%47411.07 (0.57–2.02)350.81 (0.42–1.55)491.45 (0.72–2.89)
 Q3 7.12%–<16.78%37461.35 (0.71–2.57)371.00 (0.52–1.94)521.25 (0.63–2.48)
 Q4 ≥16.78%34391.18 (0.60–2.32)0.5521.52 (0.79–2.93)0.2471.27 (0.64–2.52)0.6
  • Abbreviations: Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile4.

  • aUnconditional logistic regression analysis, adjusted for other characteristics (age, gender, H. pylori infection, drinking, and smoking status).